Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic Graft-Versus-Host Disease

Abstract

Chronic graft-versus-host disease (cGVHD) is frequent and severe after allogeneic hematopoietic stem cell transplantation (AHSCT), with unmet therapeutic needs.¹ A recent retrospective study has shown the potential efficacy of ruxolitinib, a selective Janus Kinase (JAK) 1/2 inhibitor, for the treatment of acute (n=54) and chronic GVHD (n=41) with a 81.5% and 85.4% overall response rate for acute and chronic GVHD respectively.³ There are no specific studies evaluating the efficacy of ruxolitinib in sclerodermatous skin cGVHD, a rare and difficult-to-treat form of cGVHD.

This article is protected by copyright. All rights reserved.

http://ift.tt/2oN3cBd